Melanoma is one of the most aggressive forms of skin cancer, largely due to its ability to grow rapidly and spread to other parts of the body. In this study, researchers investigated how cannabidiol (CBD) affects melanoma progression by examining its influence on gene-regulation pathways involved in cancer cell survival and metastasis. Using laboratory experiments and animal models, scientists explored whether CBD could alter molecular signaling processes that control tumor growth and cellular behavior. (pubmed.ncbi.nlm.nih.gov)

The researchers found that CBD reduced melanoma cell proliferation, limited invasive activity, and promoted programmed cancer cell death (apoptosis). A key discovery was that CBD activated the PPARγ receptor, which partnered with the enzyme TET1 to regulate DNA methylation—a process that determines whether certain genes are turned on or off. Through this mechanism, CBD increased activity of the LRSAM1 gene, which is associated with tumor-suppressing effects. These molecular changes helped slow tumor progression and reduced metastatic potential in experimental models. (pubmed.ncbi.nlm.nih.gov)

Although these findings come from preclinical research rather than human clinical trials, the study highlights CBD’s potential role in influencing cancer-related pathways through epigenetic regulation. The authors emphasize that additional studies are required to determine whether these laboratory results translate into safe and effective therapeutic strategies for people with melanoma. (pubmed.ncbi.nlm.nih.gov)

Source

Zhang X, et al. Cannabidiol inhibits melanoma progression by regulating PPARγ-TET1 complex-dependent LRSAM1 demethylation. Phytomedicine. 2026;151:157775. PMID: 41547069. National Library of Medicine, National Institutes of Health. https://pubmed.ncbi.nlm.nih.gov/41547069/